A CMS final rule codifies Medicare drug price negotiation from 2029, adds a fixed combination drug policy and implements a small biotech price floor.

Generative AI has made pharma teams faster, but real value depends on redesigning commercialization workflows, especially as ...

Nuvera’s PURE Engagement research, built on feedback from more than 2,300 physicians and support staff, ranks 2026 patient ...

Specialty distribution and provider platforms drove September-quarter profit gains at the Big Three as brand pricing weighed on results.

Siloed pricing, contracting and affordability decisions can undercut a launch. IQVIA experts explain how system-level modeling surfaces trade-offs early.

In this week’s Pharma Pulse, CVS Health plans to separate into two public companies, Bayer weighs what MFN pricing could mean ...

Accessia Health’s Tiara Green says Part D reforms eased drug costs, but premiums, deductibles and payer policies still limit patient access. Prescription drug affordability remained a major focus of ...

Emerging biotechs and large pharma companies start a launch from different positions. Jon Hamrick, partner at Curatio Advisors, explains how his firm profiles each therapy against a set of product ...

ELPRO CEO Frederik Dresen explains how cold chain monitoring moved from compliance to risk management, and what biologics and advanced therapies demand. The pharmaceutical cold chain has evolved from ...

Pharmaceutical Commerce connects biopharma executives to insights on business processes, technologies, and strategies for taking approved drugs to market.

Inizio Ignite leaders argue static, milestone-driven launch plans fall short and AI sharpens execution only when built on a sound strategy. Launching a new medicine requires a fundamentally different ...